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Abstract  
 
We present a systematic review of genome-wide research on psychotic 
experience and negative symptom traits (PENS) in the community. We integrate 
these new findings, most of which have emerged over the last four years, with 
more established behaviour genetic and epidemiological research. The review 
includes the first genome-wide association studies of PENS, including a recent 
meta-analysis, and the first SNP heritability estimates. Sample sizes of <10,000 
participants mean that no genome-wide significant variants have yet been 
replicated. Importantly, however, in the most recent and well-powered studies, 
polygenic risk score prediction and linkage disequilibrium (LD) score regression 
analyses show that all types of PENS share genetic influences with diagnosed 
schizophrenia and that negative symptom traits also share genetic influences 
with major depression. These genetic findings corroborate other evidence in 
supporting a link between PENS in the community and psychiatric conditions.  
Beyond the systematic review, we highlight recent work on gene-environment 
correlation, which appears to be a relevant process for psychotic experiences.  
Genes that influence risk factors such as tobacco use and stressful life events are 
likely to be harbouring ‘hits’ that also influence PENS.  We argue for the 
acceptance of PENS within the mainstream, as heritable traits in the same vein as 
other subclinical psychopathology and personality styles such as neuroticism. 
While acknowledging some mixed findings, new evidence shows genetic overlap 
between PENS and psychiatric conditions.  In sum, normal variations in 
adolescent and adult thinking styles, such as feeling paranoid, are heritable and 
show genetic associations with schizophrenia and major depression. 
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Introduction 
This review covers what is known about the genetic causes of psychotic 
experience and negative symptom traits (PENS) in the community. First PENS 
are introduced and the phenotypic association of PENS with psychiatric 
disorders is discussed. We then provide the first systematic review of research 
taking a genome-wide approach to PENS. Next we go beyond additive genetic 
effects to consider gene-environment correlation and gene-environment 
interaction underlying PENS. Finally we discuss this new genome-wide literature 
and consider how the field has arrived at a new position regarding the causes of 
PENS. 
 
Here PENS include positive psychotic experiences (such as paranoia and 
hallucinations), cognitive psychotic experiences (such as cognitive 
disorganisation), and negative symptom traits (such as flattened affect and lack 
of motivation). These traits are grouped together because at the extreme, they 
reflect the symptoms of psychotic disorders such as schizophrenia. While some 
groups focus solely on positive psychotic experiences, several independent 
groups now include a range of positive psychotic experiences, cognitive 
psychotic experiences and negative symptom trait measures in their studies e.g., 
(1-4).  As with all trait measures, this definition does not mean that PENS are 
equivalent to schizophrenia.  Psychosis-proneness and psychotic-like 
experiences are also labels used in a similar way to PENS (2). Schizotypy is 
another conceptualization of subclinical psychosis which is included in our 
review: it has a long history (5) and the construct overlaps with PENS.  
 
Research on psychopathological traits such as PENS is sometimes thought to 
clash with the motivations of psychiatry but the limitations and lack of 
confidence in psychiatric nosology is widely acknowledged (6-8). Common 
genetic variants act in a probabilistic manner to influence a liability for disorders 
such as schizophrenia (9, 10): as such, quantitative traits may make more sense 
than categorical diagnoses in psychiatric genetic research. Research on 
psychopathological traits such as PENS has an important role to play in terms of 
understanding the nature of individual differences in the full spectrum of 
cognition and experiences, and also in helping to understand how sometimes 
troubling traits are involved in the pathway leading up to a wide array of clinical 
diagnoses.  In fact, in a recent review, Caspi and Moffitt hypothesise that PENS 
and other related abnormal thought processes will prove to the most useful 
diagnostically under their transdiagnostic p model of psychopathology (p being a 
single dimension of general psychopathology) (8).  
 
When assessed quantitatively, it is apparent that PENS are dimensional and have 
a normal to positively skewed quantitative distribution (11).  When categorized 
as present or absent, prevalence of positive psychotic experiences has been 
estimated. For example, the lifetime prevalence estimate from the WHO World 
Mental Health Surveys of ever having positive psychotic experiences was 5.6% 
(12) see also (13-15). There are far fewer prevalence estimates of negative 
symptom traits and no consensus on how to categorise NS as present or absent. 
For example, a large community sample of young adults employed a mix of self 
report and interviewer items and reported that each individual domain of 
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negative symptoms occurred in 1.7-8.3% of participants, and 20% of the sample 
had at least one symptom (16).  Another community sample reported that 12-
13% were rated by interviewers as having negative symptoms (17). Prevalence 
rates in nonclinical samples tend to be higher for questionnaires compared to in-
person interviews, especially if the latter capture more severe negative 
symptoms such as retardation of movement (18).  In general, prevalence 
estimates of PENS are affected by measurement and where the cut-off is placed. 
An advantage of quantitative scales is the avoidance of potentially arbitrary 
choices about cut-offs and loss of power from removing quantitative 
information.   
Twin studies show that approximately a third to a half of variation in PENS is 
explained by genetic influences in adolescent samples with the remaining 
variance explained largely by nonshared environment (19-24).  Across gender, 
females tend to report more hallucinations, paranoia and cognitive 
disorganization, whereas males have higher scores on grandiosity and negative 
symptoms (11, 18, 25). 
Psychotic experience and negative symptom traits (PENS) and their 
association with psychiatric conditions  
Epidemiological evidence from multiple studies shows that positive psychotic 
experiences increase risk of developing psychiatric disorders, including 
schizophrenia, major depression and post-traumatic stress disorder (significant 
odds ratios of 1.3-5.6) (26-30). Furthermore, odds ratios increase if positive 
psychotic experiences persist over time (31). PENS are known to be associated 
with similar environmental risk factors as schizophrenia (15).  For several 
decades it has been known that relatives of individuals with schizophrenia show 
elevated rates of positive and negative schizotypal traits compared to controls 
(32, 33).  Adoption designs provided an early and very powerful means of 
showing that wider schizophrenia “spectrum” disorders and schizotypal 
personality disorder were elevated in biological relatives of adoptees with 
schizophrenia, thus suggesting a genetic link with these disorders and 
schizophrenia (34, 35) 
 
Research has attempted to explore empirically if a “cut off” is evident in the 
spectrum of positive psychotic experiences that might suggest a qualitative 
distinction between positive psychotic experiences in the community and 
extreme psychotic experiences in the clinic.  For example, is subclinical paranoia 
that many people experience part of a continuum with severe paranoia that is 
considered a clinical symptom? (36) After all, individuals suffering from severe 
positive psychotic experiences such as delusions are known to lose insight into 
their own experiences, which might suggest a qualitative difference between 
subclinical and clinical PENS.  
 
Several taxometric analyses support a fully dimensional model of positive 
psychotic experiences: that is, evidence does not suggest discontinuity between 
milder and more severe forms of positive psychotic experiences (37-39). A large 
adolescent twin study demonstrated that the heritability of PENS does not 
 
 
5 
change significantly across the severity spectrum (23). Another study rated 
families according to their ‘level’ of psychosis as a proxy for genetic risk, varying 
from nothing i.e. no psychotic experiences or subclinical psychotic experiences, 
to ‘low’ or ‘high’ impact psychotic symptoms, and clinical psychosis (40). Rates of 
mental illness in a selected “proband” within each family increased linearly 
across these severity levels (40). These forms of evidence largely support 
continuity across the PENS severity spectrum.   
 
Yet there is evidence also to suggest discontinuity. Negative symptom traits 
show evidence of higher heritability in adolescence at the impaired extreme than 
in the normal range within the community (23) and the above family study also 
found some evidence of non-linearity across the psychosis spectrum in families 
with more than one individual with mental illness (40). Heritability estimates of 
schizophrenia are considerably higher than of PENS in the community (80% 
versus 30-50%, respectively) (23, 41) but it is not a like for like comparison 
because the schizophrenia estimate assumes an underlying liability. While the 
question of a qualitative cut off is not settled, as discussed below in our 
systematic review, genome-wide studies have considerably advanced our 
understanding of the link between psychiatric conditions and PENS through 
estimating shared genetic variance using measured DNA variants (1, 3, 4, 42-47).   
 
Systematic review of genome-wide studies of psychotic experiences and 
negative symptoms traits (PENS) 
Inclusion/exclusion criteria 
In this systematic review, all genome-wide studies of PENS with any of the 
following aims were included: 
1) To identify common genetic variation in a genome-wide association study 
of PENS assessed using questionnaire or interview, and categorical or 
dimensional scales. 
2) To estimate variance in PENS attributable to common genetic variation 
using genome-wide genotypic data. 
3) To evaluate at a genome-wide level the genetic association between PENS 
and other phenotypes. 
 
Data sources and search terms 
To identify all papers, a series of search terms were used in PubMed to capture 
relevant studies published on PubMed before the 21st of February 2018 in terms 
of phenotype and type of analysis. The search was conducted using the following 
argument: (psychotic OR psychosis OR schizotypy OR schizotypal OR psychotic 
experiences OR psychotic-like-experiences OR prodromal OR psychosis 
proneness OR paranoia OR hallucinations OR anhedonia OR negative symptoms 
OR cognitive disorganisation OR cognitive disorganization OR grandiosity OR 
delusions) AND (gwas OR genome-wide OR polygenic OR gcta OR greml OR SNP 
heritability OR ldsc OR ld score regression).  
 
The resulting publications were then selected for review based on the following 
criteria: 
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1) Studies using genome-wide array or sequence data. Studies using linkage 
analysis and candidate genes were not included in this review. 
2) Studies focusing on at least one dimension of PENS in a general 
population sample. This does not include studies focusing on psychosis 
symptoms in a clinical sample, nor does it include studies regarding only 
psychosis endophenotypes, such as ERP, EEG, or brain metrics. If other 
phenotypes were analysed, only the results referring to PENS are 
discussed. 
3) Studies reported in English. 
 
In addition to the systematic database search using PubMed, bibliographies of 
original research and review papers were investigated by hand to identify 
additional studies meeting the above criteria. 
 
Data collection 
From the initial search on PubMed, 1342 papers were returned. Based on the 
title and abstract, 1315 were excluded by one author (O.P.), leaving 29 papers for 
further consideration. After closer reading of the remaining 29 papers, 19 were 
excluded (reasons for exclusion of the 19 papers provided in Supplementary 
Information Table S1). Ten papers remained after these exclusions. The number 
of papers identified by looking through reference lists was 0.  Three other 
studies were identified by the authors through reading unpublished manuscripts 
on Biorxiv or from being involved in the work or citing the studies (1, 48, 49), 
making a total of 13 studies. Results were summarised in a table form.  
Results of systematic review 
Thirteen publications were identified as genome-wide studies of PENS using the 
above search terms on the 21st of February 2018 (Table 1).  
 
Insert Table 1 here 
 
SNP heritability studies. The review revealed that three studies to date have 
estimated the SNP heritability of PENS (1, 2, 50) (see Table 1). Figure 1 shows 
the twin and SNP heritability estimates for specific PENS from the largest 
respective studies (1, 23).  SNP heritability estimates of PENS are modest with 
non-significant differences in estimates across types of PENS. As with many 
traits and disorders, SNP heritability estimates are lower than the twin 
heritability estimates (51, 52). Of the 3 studies, two are from individual samples, 
the UK Twins Early Development Study (TEDS) assessed at age 16 years (50, 51), 
and the Northern Finland Birth Cohort 1966 study assessed at age 31 years (2). 
The third and largest study is a meta-analysis of three samples including TEDS, 
as well as the Child and Adolescent Twin Study in Sweden (CATSS) and the Avon 
Longitudinal Study of Parents and Children (ALSPAC), who were all assessed in 
mid to late adolescence (1).  
 
Insert Figure 1 here 
 
In relation to these new SNP heritability results, it is noted that there are several 
different methodologies available; two of the most commonly used are linkage 
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disequilibrium (LD) score regression (53) and genomic-relatedness-matrix 
restricted maximum likelihood (GREML) (54). GREML is based on the 
relationship between phenotypic and genotypic similarity between individuals 
(thus requiring individual-level genotypic and phenotypic data). In contrast, LD 
score regression calculates SNP heritability from the relationship between each 
genetic variants’ genome-wide association study (GWAS) derived effect size (chi-
square) and LD-score (thus requiring only GWAS summary statistics). Two of the 
studies employed GREML (2, 50), whereas the meta-analysis had enough power 
to use both LD score regression and GREML (1). As shown in Figure 1, LD score 
estimates are higher than the GREML estimates with overlapping confidence 
intervals.  
 
A second point about the SNP heritability estimates in Figure 1 is that they are 
based on normalised PENS scores due to positive skew (1). Normalisation to 
reduce skew is standard practice but it can introduce artificial variance (i.e. 
noise) and thereby reduce SNP heritability estimates. Normalisation will have a 
larger effect on more highly skewed variables, which could explain why in Figure 
1 the more skewed PENS (paranoia and hallucinations combined scale and 
parent-rated negative symptoms) show a lower SNP heritability than less 
skewed PENS traits (cognitive disorganisation and anhedonia). Although GREML 
SNP heritability estimates were consistent when using untransformed PENS 
scores (51, 55), it has been reported that GREML underestimates the SNP 
heritability of skewed traits (56). Simulation studies are required to investigate 
the effect of skew on estimates of SNP heritability. 
 
Finally, minor allele frequency (MAF)-stratified SNP heritability analyses have 
been reported on one of the SNP heritability studies. In the TEDS sample with 
approximately 2100 individuals, results suggested that the majority of the 
anhedonia SNP heritability was explained by variants with MAF<.05 (50).  
Estimation of SNP heritability stratified by MAF is a means to understand the 
genetic architecture of a trait in terms of MAF. Further studies are needed in 
larger samples, given the demands on power of this approach due to the larger 
number of estimated parameters.  
 
In sum, PENS appear to be influenced by additive genetic influences, with some 
modest differences in heritability estimates across specific types of PENS.  
Samples are still relatively small (largest sample is 8665 including related 
cotwins) and it is known that different programs produce slightly different 
estimates (57).  
 
Genome-wide association studies. The search identified three GWAS to date 
aiming to identify new variants associated with PENS: two on individual samples 
and one mega-analysis combining three cohorts. The first study was on 
participants in the ALSPAC cohort, who were assessed at ages 12 and 18 on 
positive psychotic experiences using interview measures (43).  Second, the 
Northern Finland Birth Cohort (NFBC) self-reported on a range of PENS domains 
at age 31 years (2) (see further study on same sample stratified by DISC1 (58)). 
Finally a mega-analysis on the TEDS, ALSPAC and CATSS samples reported on 
results from mid-adolescence combining data on self-reported positive and 
 
 
8 
cognitive PENS and parent-rated negative PENS (1).  The latter two GWAS 
studies each identified one genome-wide significant variant, but neither of these 
genome-wide significant variants has been replicated in an independent sample.  
 
Polygenic risk score studies. As shown in Table 1, 10 studies to date have explored 
genetic overlap between genome-wide common variant genetic risk for other 
phenotypes and PENS.  In all but one of these studies (59) the other phenotypes 
were psychiatric disorders, most commonly schizophrenia, using PRS derived 
from the PGC (http://www.med.unc.edu/pgc).  The 10 studies can be broadly 
categorized into those that studied association between selected genome-wide 
significant SNPs and PENS (43, 45, 47), those testing the association between 
PRS derived from PGC1 and PENS (42, 43), and those testing the association 
between PRS derived from PGC2 and PENS using samples of <2500 (4, 45, 48) 
and >2500 individuals (1, 44, 46). Finally one study also reported on PRS 
associations using phenotypes outside of PGC with PENS (59). All the studies 
using the PGC2 SCZ PRS or PGC1 MDD PRS with samples >2500, and one smaller 
study (4), report significant genetic association between PENS and psychiatric 
disorders (schizophrenia or major depression) (1) (44, 46). The other studies 
using PGC2 with n<2500 samples or using selected SNPs or the PGC1 PRSs 
reported non-significant findings or negative associations. 
 
As such there are four studies reporting a significant genetic link between 
schizophrenia and PENS in the community (1, 4, 44, 46) (Table 1 and Figure 2). 
Effect sizes in terms of percent variance explained in PENS by the schizophrenia 
PGC2 PRS ranged between .08%-.7%, with one study not reporting effect sizes 
(4).  In terms of positive psychotic experiences, within these four studies, some 
consistencies and discrepancies emerge.  Of the two studies using interview 
measures of positive psychotic experiences, one reported a significant 
association with schizophrenia PRS in adults (4) while the other did not find this 
in adolescents (44). Of the three studies using questionnaire measures of 
positive psychotic experiences, two of the studies were on adolescents and 
reported a significant positive association with schizophrenia PRS (1, 46). A third 
smaller study, on adults, did not find an association (4). Notably, the largest 
study found that this association only held in the non-zero scorers (see Figure 2) 
(1).   
 
Insert Figure 2 here 
 
Schizophrenia PGC2 PRS was shown to predict negative symptom traits in 
adolescence across three studies, as assessed by self, parent report and 
interview, respectively (1, 4, 44), although there was a significant association in 
the smaller study only for the interview data and not the self-rated 
questionnaires (4). Schizophrenia PRS also predicted self-rated cognitive 
disorganization and anhedonia in the only study to include these domains (1).   
 
In terms of PRS for phenotypes other than schizophrenia, one study found the 
major depression PRS and this study found to share genetic influences with 
negative symptoms and anhedonia but not positive or cognitive PENS (1). In the 
two studies where bipolar disorder PRS was employed, it did not show a 
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significant positive association with PENS (1, 45). In the meta-analysis, a 
significant negative association between PRS for bipolar disorder and adolescent 
paranoia and hallucinations was identified (r2 = 0.12%)(Figure 1) (1).  Finally, in 
a large multi-phenome analysis, no associations between PENS and PRS were 
significant after correcting for multiple testing but a small number were 
nominally significant (59) (see Table 1). 
 
GxE studies. Gene-environment interaction (GxE) analyses on PENS using 
genome-wide data are reported in two studies in Table 1 (3, 47) as well as one 
unpublished thesis known to the authors (60). The only positive GxE finding at a 
genome-wide level is that high birth weight appears to interact with selected 
genome-wide SNPs from PGC2 schizophrenia in predicting more social 
anhedonia (47). Other work found that the stress of signing up as a conscript 
interacted with the PGC2 Schizophrenia PRS in predicting less schizotypy 
(although not all subscales were significant) (3). Finally, no interactions were 
reported between adolescent cannabis use, tobacco use or psychosis family 
history and the PGC2 schizophrenia PRS in predicting PENS in the TEDS sample 
in adolescence (60).  
 
Beyond additive genetic effects: Gene-environment correlation and PENS 
Here we move beyond the systematic review to discuss briefly research that is 
showing that environmental variables associated with PENS are in some cases 
tied in with genetic predisposition. We exemplify this point by describing a 
selection of recent findings from our group and others. We acknowledge parallel 
work in this area on schizophrenia e.g., (61) but, as with other sections of this 
review, we focus on PENS in the community. 
It is well established that our environment is not independent of our 
genotype, with many “environments” being heritable (62, 63).  Passive gene-
environment correlation (passive rGE) exists due to the home environment 
being influenced by the parents’ genotype and biological children inheriting 
some of their genotype.  Individuals’ active behaviour leads to an individual 
experiencing environments that link to their genotype (active rGE) and 
individuals evoke environmental responses from their genetically influenced 
behaviour (evocative rGE).  
Using twin models to partition variation in genetic and environmental 
effects, a set of studies based on the TEDS community sample reported that in 
adolescence, cannabis use, bullying victimization and stressful life events were 
all partly heritable (64-66). In the case of bullying victimization and stressful life 
events, the genetic influences were partly overlapping with some PENS domains 
(65, 66). While such evidence does not rule out the possibility that some 
covariation between PENS and environmental risk factors is in fact 
environmental see e.g., (67), it suggests shared genetic pathways are in 
operation as well.  
In terms of cannabis use, having ever used cannabis by age 16 was found 
to be 37% heritable in TEDS but covariation with psychotic experiences was 
explained fully by shared environmental factors (64).  In an older sample of 19-
36 year olds, and assessing cannabis use disorder rather than never/ever use, 
correlation with psychotic experiences (primarily positive psychotic experiences 
with two items relating to movement) was explained by both genetic and 
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environmental influences (68) suggesting some gene-environment correlation 
underlying the relationship with cannabis use disorder.   
While the above rGE research might to some degree suggest a diminished 
role of environment on PENS, other new findings suggest that direct genetic 
effects may be inflated and actually harbour environmental processes from 
parenting. Parental genotypes that are not transmitted to offspring have recently 
been shown, when assessed as a polygenic score, to predict significantly the 
offspring’s phenotype (69, 70).  Concerns remain as to how assortative mating 
and genetic influences on other phenotypes are controlled for, but Kong et al 
(2018) conclude that GWAS direct effects may be inflated because part of the 
GWAS signal operates via “genetic nurture” -- the effects of the parents’ 
nontransmitted alleles on the rearing environment of the child. Educational 
attainment was their example phenotype, but this process of genetic nurture 
may extend to other phenotypes, such as PENS.   
In sum, while direct additive genetic effects and direct additive 
environmental effects are likely involved in PENS, approaches that can capture 
genetic effects within the context of environment, and environment within the 
context of genetics are likely to be fruitful for understanding the etiology of PENS 
in full.  We predict that successful identification of causal genetic variants 
associated with PENS will be aided by research on “environmental risk factors”, 
such as smoking, cannabis use, urbanicity, stressful life events, and bullying 
victimization.   
 
Discussion 
 
To our knowledge this is the first systematic review of genetic research on PENS 
For a review of research on phenotypes associated with genetic risk for 
schizophrenia please see (71).  Based on recent genome-wide research, a new 
position has been reached in our understanding of psychotic experience and 
negative symptom traits (PENS) in the community. The new research stemming 
from four studies suggests that genetic risk for diagnosed schizophrenia overlaps 
significantly with the genetic causes of PENS in the community during 
adolescence and adulthood (1, 4, 44, 46). To some degree, normal variation in 
adolescent and adult thinking styles, such as feeling paranoid, is caused by the 
same common genes that influence risk for schizophrenia. At the same time, the 
magnitude of the genetic association from current evidence does not suggest that 
PENS and schizophrenia are equivalent or that PENS should be used instead of or 
as a proxy for schizophrenia in genetic research. In the same vein, genetic risk 
for major depression overlaps significantly with negative symptom traits in the 
community (1) yet the modest associations do not suggest that negative 
symptom traits and major depressive disorder are interchangeable or 
completely equivalent at a genetic level.  
How does the effect size for the PENS-schizophrenia genetic overlap 
compare to other trait-psychiatric disorder pairings?  The percent variance in 
PENS explained by schizophrenia genetic scores is between .08-.7% in the most 
recent well-powered studies (1, 44, 46) with one study reporting a positive 
association but not including effect sizes (4).  One study reported that the major 
depression PRS predicted .08-.11% variance in negative symptom traits in the 
community (1). Similar percent variance was explained for other trait-
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psychiatric disorder pairings in a recent study on the CATSS sample (46).  
Importantly, the degree to which a PRS predicts a different phenotype (for 
example, schizophrenia genetic risk predicting PENS) is capped at the amount of 
variance a PRS can explain of its own phenotype in an independent sample. The 
schizophrenia PGC2 PRS explained 7% variance in liability to schizophrenia in an 
independent sample (10). The largest effect size for the schizophrenia PRS 
explaining any individual PENS is .7%, thus it is about 10% of the size of how 
strongly it predicts liability to schizophrenia (.7/7%). The MDD PGC1 PRS 
explained 0.72% variance in MDD on a liability scale (based on the authors’ 
calculations) (72). The effect size for the MDD PRS explaining negative symptom 
traits in the community in adolescence appears to be 15% of the size (.11/.72). 
As a comparison, the ASD PRS predicts 1.13% variance in ASD on a liability scale 
in an independent sample  (Grove et al 2018) and .1% variance in ASD traits in 
the community (46), that is, (.1/1.13) 9% of the size.  The MDD PRS predicts 
0.72% variance in MDD on a liability scale in an independent sample (72) and 
.2% variance in MDD traits in the community (46), that is, (.2/.72) 28% of the 
size.  Finally, the ADHD PRS predicts 1.03% variance in ADHD on a liability scale 
in an independent sample (73) and 0.8% variance in ADHD traits in the 
community (46), that is, (.8/1.03) 78% of the size.  We note some caveats in 
these calculations because the ‘target’ sample used to derive PRS estimates 
differs for the clinical and community studies.  
Nevertheless, these ballpark estimates suggest that the genetic link 
between PENS and schizophrenia, when the reliability of the PRS is taken into 
account, is similar to other psychopathological trait-disorder pairings such as 
ASD and weaker than major depression and ADHD which show stronger genetic 
links between trait and disorder.  What would cause a disorder PRS such as 
schizophrenia to predict less variance in PENS than in schizophrenia itself? It is 
noted that most of the results for PENS comes from adolescent samples (1, 44, 
46) (although not all e.g., (4)). This is relevant because PENS may not have 
emerged in all people by adolescence and as such adolescent PENS will reflect a 
developmentally specific form of PENS. In contrast the schizophrenia PRS is 
derived from adult samples.  As such adolescent PENS may overlap to a lesser 
degree with the schizophrenia PRS than lifetime PENS; this can be tested in 
future work on older samples. In the meta-analysis report (1), and shown in 
Figure 2, paranoia and hallucinations was only significantly positively predicted 
by the schizophrenia PRS in the non-zero scorers. Teenagers who reported no 
paranoia and hallucinations during mid-adolescence existed anywhere on the 
schizophrenia genetic liability spectrum (1).  
A second potential reason for weaker genetic links between PENS and 
schizophrenia than with schizophrenia itself is the diagnosis of schizophrenia. It 
requires individuals to show multiple symptoms that have parallels in PENS, but 
PENS are typically measured as individual traits (paranoia, hallucinations, 
cognitive disorganisation, anhedonia, and so forth). It is realistic to predict that 
the schizophrenia PRS would explain more variance if multiple PENS were 
included in an analysis together.  
Not all the studies addressing the link between schizophrenia PRS and 
PENS found a significant association. In our systematic review we noticed a 
pattern which is that the studies using an older, less reliable PRS (the “PGC1” 
version), as well as smaller studies tended not to find significant associations, 
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whereas all the studies using the more reliable PGC2 PRS with samples over 
2500 (as well as one smaller study (4)) reported some significant positive 
associations between schizophrenia and PENS.  As noted elsewhere, long-term 
prospective cohorts such as ALSPAC may have attrition bias whereby individuals 
with high schizophrenia PRS selectively drop out and this will under-power 
analyses in those cohorts (74) 
The negative association between bipolar disorder PRS and PENS may be 
due to a lack of reliability in the available bipolar disorder PRS; future research 
can test this further (1, 45).  
Our review shows that recent genome-wide research corroborates twin 
research in showing modest additive genetic influences on PENS. SNP 
heritability estimates are now reported for PENS using a variety of methods 
(GREML, LD score, MAF-stratified) and for adolescents and young adults (1, 2, 
50). While the SNP heritability estimates may seem low, particularly for the 
estimates from adolescent samples (1) the estimates are consistent with child 
and adolescent psychopathology in which modest SNP heritability estimates are 
being reported across a range of traits (51).  Considerations such as which SNP 
heritability method is chosen (57), how linkage disequilibrium is handled (50), 
and how skew is handled (1), along with reliability of items and informant will 
affect estimates (51).   
One possibility regarding apparent genetic links between PENS and 
schizophrenia is that individuals with the illness in a community sample 
assessed on PENS might be driving any apparent association between 
schizophrenia genetic risk and PENS.  The findings by van Os and colleagues 
allay this concern however because they find a positive association between the 
schizophrenia PGC2 PRS and PENS in general community controls with no family 
history of schizophrenia, to a stronger degree than in relatives of individuals 
with psychotic disorders (4). Furthermore, another of the studies showed that 
the positive associations between schizophrenia PGC2 PRS and negative 
symptoms still held when individuals with a diagnosed psychotic disorder were 
removed from the sample and when individuals with a parent with a diagnosed 
psychotic disorder were removed from the sample (44).     
These initial findings raise interesting questions for future research. 
Would a measure of stable PENS across time show a stronger genetic link with 
schizophrenia than PENS assessed cross-sectionally? Is it essential, as some 
suggest, to control for confounds such as anxiety or other PENS when assessing 
the link between a specific PENS domains and another phenotype (4, 44)?   This 
is a more stringent approach that does not allow for natural covariation between 
PENS domains; we know that PENS domains correlate positively and show some 
genetic overlap between them e.g., (2, 23). 
We acknowledge some limitations to the scope of our review. The type of 
genetic research we reviewed focuses on common additive genetic variation. We 
limited our review to measures of PENS in the community. It is not yet known to 
what degree PENS are genetically related to other types of psychiatric disorders. 
In depth considerations of measurement of PENS were beyond the scope of this 
review but, as with all complex traits, are a critical issue (75)(11).   
PENS in the community and psychiatric disorders, particularly 
schizophrenia, have for a long time appeared to be associated with one another.  
The new genome-wide genetic research reviewed here acts both to establish 
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concretely that PENS and schizophrenia are genetically linked, but also to show 
that the genetic link is present but mild.  Genetic correlation or genetic 
covariance estimates only take causal models so far (76).  To find out what 
underlies the purported genetic overlap indicated by a significant genetic 
correlation between two phenotypes, further evidence is needed. Examples 
include finding out the correlation of variant effect sizes across the two 
phenotypes, or through learning about the molecular action of a genetic variant 
in relation to two phenotypes.   
The practical utility of new knowledge about the genetic basis of PENS 
deserves discussion.  For example, with increasing knowledge from 
epidemiology and psychiatric genetics regarding the link between PENS and 
psychiatric disorders, informed decisions can be made about the place PENS can 
have in aiding prevention and intervention of mental health conditions. Second, 
their role in contributing to new models of psychopathology has recently been 
proposed (8). 
Whether PENS form part of a “psychosis continuum” with clinical 
schizophrenia -- in the sense that PENS are a milder manifestation of the same 
phenotype as schizophrenia -- has been questioned for many years, and as 
discussed earlier, taxometric, twin and family studies have attempted to test this 
continuum hypothesis empirically (23, 32, 37-40).  The new finding of a degree 
of genetic overlap between PENS and schizophrenia supports an at least partial 
aetiological continuum.  A more far-reaching question is how useful PENS can be 
as a transdiagnostic predictor of the p (psychopathology) factor (8).  The 
biologically-driven information derived from this new genome-wide research 
takes PENS research to a new position, in terms of new forms of evidence and 
models. Genome-wide research allows the mechanisms of the cognitions, 
behaviours and perceptual experiences that underlie PENS in the community to 
begin to be understood at a molecular level.   
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Figure legends 
 
Figure 1. SNP heritability estimates and twin heritability estimates for psychotic 
experiences and negative symptom traits (PENS) in the community. SNP and 
twin heritability estimates come from the largest respective studies (1, 23) and 
are shown with standard errors and 95% confidence intervals, respectively. For 
SNP heritability estimates, * p < 0.05; **p < 0.01.  
 
 
Figure 2. Polygenic risk scores for schizophrenia, bipolar disorder and major 
depression and their prediction of adolescent psychotic experiences and 
negative symptom traits (PENS) in the community from a recent meta-analysis 
(1). Published by John Wiley & Sons Ltd. © The Authors. American Journal of 
Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley 
Periodicals, Inc. 
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Table 1. Genome-wide studies of psychotic experiences and negative symptom traits (PENS) in the community. 
Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Tomppo 
et al., 
2012 (58) 
GWAS Northern Finland Birth Cohort 
1966 (NFBC66) (77): N = 4,561 
unrelated individuals assessed 
at age 31 years. Individuals 
were stratified based on DISC1 
genotypes. 
Self-report Revised Social 
Anhedonia Scale (SAS) 
and Revised Physical 
Anhedonia Scale (PHAS) 
(78). 
GWAS: Univariate GWASs for each 
scale were performed within DISC1 
genotype-based subgroups of the 
sample. Three groups derived 
called 'risk', 'protective', and 
'neutral', containing 3054, 962 and 
545 individuals respectively. 
Univariate GWAS also performed 
using the whole sample with DISC1 
genotype as covariate. In total, 8 
GWAS performed. Pathway 
analysis used to characterise 
relationship between implicated 
genes and the DISC1 pathway, and 
functional enrichment analysis for 
implicated micro RNAs. 
GWAS: No genome-wide significant 
markers across all GWASs. 18 loci 
suggestively associated based on three or 
more variants within a 300kb window with 
p<1×10-3. Ingenuity Pathway Analysis 
demonstrated 7 of 24 genes implicated by 
suggestive loci (p<1×10-3) were involved in 
the DISC1 pathway. Two microRNAs were 
within suggestive loci.  
Derks et 
al., 2012 
(42) 
PRS Sample of schizophrenia cases 
and controls from The 
Netherlands. Analyses on 
controls discussed as per this 
review’s inclusion criteria. 
Controls had no family history 
of psychiatric disorder. N = 148 
control individuals assessed for 
psychotic symptom dimensions. 
Structured interview by 
clinician using the 
Comprehensive 
Assessment of Symptoms 
and History (CASH) (79). 
Psychotic symptom 
dimensions, derived from 
factor analysis were 
Disorganisation, Positive, 
Negative, Mania, and 
Depression. 
PRS analysis: Tested for Pearson 
correlation between genetic risk 
for schizophrenia (PGC1) (80) and 
psychotic symptom dimension 
scores in control individuals. 
Sensitivity analyses were 
performed to assess the variance 
explained by ancestry components. 
No significant association identified 
between schizophrenia genetic risk and 
psychotic symptom dimensions in the 
control individuals. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Zammit et 
al., 2014 
(43)  
GWAS; 
PRS 
Avon Longitudinal Study of 
Parents and Children (ALSPAC) 
(81): N = 3,483 unrelated 
individuals assessed at 12 and 
18 years. Definite and none 
psychotic experience groups (N 
= 424 and 3,059, respectively) 
defined by at least one definite 
psychotic experience at either 
12 or 18. 
Secondary analysis was 
performed where definite/none 
psychotic experience groups 
were defined by at least one 
definite or suspected psychotic 
experience at either age (N = 
912 and 2,588, respectively). 
Semi-structured 
interview using the 
Psychosis-like Symptoms 
interview (PLIKSi) (30): 
based on the Schedule for 
Clinical Assessment in 
Psychiatry (SCAN). 
Included 11 questions 
assessing hallucinations, 
delusions, and thought 
interference. 
Candidate variation analysis based 
on previously associated genetic 
variation for schizophrenia. 
GWAS: Logistic regression to 
identify genetic variants associated 
with definite/none psychotic 
experience groups. 
PRS analysis: Logistic regression to 
test for association between 
schizophrenia genetic risk (PGC1) 
(80) and definite/none psychotic 
experience groups. 
Candidate variation analysis: No variant 
achieved significance after correcting 
multiple testing. 
GWAS: No variant achieved genome-wide 
significance (p<5×10-8). 121 variants 
achieved p<5×10-5 representing 31 
independent signals. 
PRS: No significant association between 
schizophrenia PRS and definite/none 
psychotic experience groups. Secondary 
analyses with broader phenotype were the 
same as primary analysis. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Sieradzka 
et al., 
2014 (45)  
PRS Discovery sample: Twins Early 
Development Study (TEDS) 
(82): N = 2,152 unrelated 
individuals assessed at 16 
years. 
Replication sample: ALSPAC 
(81): N = 3,427 unrelated 
individuals assessed at age 16 
years. 
Discovery sample: 
Specific Psychotic 
Experiences 
Questionnaire (SPEQ) 
(11): Contains six 
subscales assessing PENS 
domains including self-
reported Paranoia, 
Hallucinations, 
Grandiosity, Cognitive 
Disorganisation, 
Anhedonia and parent-
report Negative 
Symptoms. 
Replication sample: Self-
reported Psychosis-like 
Symptoms Questionnaire 
(PLIKS-Q)(83). Assesses 
positive symptoms 
including paranoia, 
hallucinations and 
delusions. 
Candidate variation analysis: 
Variants selected based on 
previously associated genetic 
variation for schizophrenia. First in 
TEDS, with any significant SNPs 
replicated in ALSPAC. 
PRS analysis: Linear regression to 
test for association between 
schizophrenia genetic risk (PGC2) 
(10), bipolar disorder, and specific 
PENS within TEDS. A one-tailed 
hypothesis that there would be a 
positive association was used. 
Genome-wide significant variation 
risk scoring: Tested for association 
between PENS and risk scores 
based on SNPs previously 
associated with schizophrenia at 
genome-wide significance. 
Candidate variation analysis: After 
accounting for multiple testing, no 
candidate variation achieved significance. 
The strongest evidence for association was 
within Transcription Factor 4 (TCF4). The 
association between candidate SNPs within 
TCF4 were not significant in the replication 
sample. 
PRS: No significant positive association 
between PENS and schizophrenia PRS. 
Although a one tailed hypothesis was 
employed, there were nominally significant 
negative associations between 
schizophrenia genetic risk, Anhedonia and 
Negative Symptoms, and bipolar disorder 
genetic risk and Anhedonia. 
Genome-wide significant variation risk 
scoring: The schizophrenia composite score 
based on selected genome-wide significant 
genetic variation did not significantly 
predict any adolescent PENS. 
Sieradzka 
et al., 
2015 (50)  
SNP h2 TEDS (82): N = 2,152 unrelated 
individuals assessed at 16. 
Specific Psychotic 
Experiences 
Questionnaire (SPEQ) 
(11): see above. 
Estimating SNP heritability: This 
was performed using GREML in 
GCTA (84). 
Estimating SNP heritability: SNP 
heritability estimates for Paranoia (14%), 
Cognitive Disorganisation (19%), 
Grandiosity (17%) and Anhedonia (20%) 
suggest their variation is in part 
attributable to common genetic variation. 
Large standard errors due to sample size. 
Hallucinations and Negative Symptoms 
showed no evidence of non-zero SNP 
heritability. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Krapohl et 
al., 2016 
(48)  
PRS TEDS (82): N = 2,152 unrelated 
individuals assessed for PENS at 
16 years. Same sample as 
Sieradzka et al 2014 (45) above. 
As part of a phenome-
wide cohort study on 
many adolescent 
outcomes, PENS captured 
using SPEQ (11) 
(described above). 
PRS analysis: Tested for association 
between adolescent paranoia, 
grandiosity, cognitive 
disorganisation and negative 
symptoms (and other adolescent 
behaviours) and PRSs for 
schizophrenia (PGC2) (10), major 
depressive disorder (85), bipolar 
disorder (86), ADHD (87), autism 
(87), adult IQ (88), child IQ (89), 
intracranial volume (90), ever 
smoked (91), educational 
attainment (92), Alzheimer's (93), 
body mass index (94) and height 
(95). 
Results showed no significant associations 
after multiple testing was accounted for. 
Nominally significant negative associations 
were found between Negative Symptoms 
and educational attainment, Grandiosity 
and ever smoked, and Cognitive 
Disorganisation and height. A nominally 
significant positive association was 
identified between Grandiosity and body 
mass index. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Jones et 
al., 2016 
(44)  
PRS ALSPAC (81): Sample included 
unrelated individuals only. 
N = 5,444 individuals assessed 
for positive symptoms at 12 or 
18 years. Definite and none 
positive symptom groups 
(N=419 and 5,025 respectively) 
defined by at least one definite 
psychotic experience at either 
12 or 18. 
N = 3,673 individuals assessed 
for negative symptoms at 16.5 
years. High/low negative 
symptom groups: N = 337 and 
3,336 respectively. 
N = 4,106 individuals assessed 
for depression outcome 
likelihood at 15.5 years. 
High/low groups: N= 373 and 
3,733 respectively. 
N = 4,107 individuals assessed 
for anxiety outcome likelihood 
at 15.5 years. High/low groups: 
N = 444 and 3,663 respectively. 
Positive symptoms were 
assessed using the PLIKSi 
(30) (described above). 
Negative psychosis-like 
symptoms were assessed 
using a subset of 10 
items from the 
Community Assessment 
of Psychotic Experiences 
(CAPE) self-report 
questionnaire (96). This 
measure assessed 
features such as apathy, 
anergia and asociality. 
Depressive and anxiety 
disorder outcomes were 
derived from the semi-
structured Development 
and Well-Being 
Assessment (DAWBA) 
semi-structured 
interview (97, 98). 
PRS analysis: Tested for association 
between genetic risk for 
schizophrenia (PGC2) (10) and 
positive symptoms, negative 
symptoms, anxiety and depression 
disorders using logistic regression. 
Sensitivity analyses performed to 
determine whether effects varied 
when using different thresholds to 
distinguish groups, varying 
measurement cut-offs or tools, the 
effect of including individuals with 
a psychotic disorder diagnosis at 
age 18, and the effect of including 
individuals with a parent with a 
diagnosis of a psychotic disorder. 
PRS analysis: A significant positive 
association between schizophrenia PRS and 
negative symptoms (OR = 1.21; r2 = 0.7%) 
and anxiety disorder (OR = 1.17; r2 = 0.5%) 
was reported. Positive symptoms showed a 
near significant positive association when 
using more relaxed p-value thresholds for 
the PRS but a near significant negative 
association when using a stringent p-value 
threshold for the PRS. 
Sensitivity analyses demonstrated that the 
results were consistent when using 
different thresholds to determine the 
phenotypic groups. Results were also 
consistent when combining interview and 
questionnaire data of positive psychotic 
experiences, when excluding individuals 
with a psychotic disorder diagnosis at age 
18, or when excluding individuals with a 
parent with a diagnosis of a psychotic 
disorder.  Associations with negative 
symptoms and anxiety disorder persisted 
when including the other measures in a 
multivariate model 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Van Os et 
al., 2017 
(4)  
PRS Genetic Risk and Outcome of 
Psychosis (GROUP) study (99): 
N = 871 siblings and 812 
parents of patients with 
psychotic disorder, and N = 523 
healthy individuals. Mean ages: 
healthy controls = 31.10 years, 
siblings = 27.85 years, parents = 
54.83 years. 
Individuals assessed 
using self-report CAPE 
questionnaire (described 
above) and the 
structured interview by 
clinicians using the 
Structured interview for 
Schizotypy - Revised 
(SIS-R) (100, 101). CAPE 
included positive, 
negative and depressive 
symptom subscales. SIS-
R contained positive and 
negative schizotypy 
subscales. 
PRS analysis: Tested for association 
between schizophrenia (PGC2) 
(10) PRS and CAPE and SIS-R totals 
and subscales. IQ included as 
covariate. Relatives of psychotic 
individuals and healthy controls 
were analysed separately. 
Relatedness between siblings and 
parents controlled using mixed 
linear modelling. The 
independence of associations for 
each subscale was assessed by 
covarying for all other subscales. 
Variance explained by the 
schizophrenia PRS was not 
estimated. 
Among relatives of patients, significant 
positive associations between 
schizophrenia PRS and CAPE total, CAPE 
depressive, SIS-R total and SIS-R positive 
scores were identified, but not for CAPE 
positive, CAPE negative, or SIS-R negative. 
Secondary analyses showed that only CAPE 
depressive symptoms were significantly 
associated with schizophrenia PRS when 
accounting for all other PENS dimension 
scores and IQ. 
Among healthy individuals, significant 
positive associations between 
schizophrenia PRS and all SIS-R scores 
(total, positive, and negative) were 
identified, but not for any CAPE measures. 
Secondary analyses showed that only the 
SIS-R positive subscale showed a significant 
positive association with schizophrenia PRS 
when accounting for other scales. 
Secondary analyses showed a significant 
negative association between 
schizophrenia PRS and CAPE negative 
scores when accounting for covariance with 
other subscales. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Ortega-
Alonso et 
al., 2017 
(2)  
GWAS; 
SNP h2 
NFBC66: N = maximum of 4,269 
unrelated individuals assessed 
at age 31. 
Self-report psychosis 
proness questionnaires 
were used: Perceptual 
Aberration Scale (PAS) 
(102), Hypomanic 
Personality Scale (HPS) 
(103), Revised Social 
Anhedonia Scale (SAS), 
Revised Physical 
Anhedonia Scale (PHAS) 
(78), and the Schizoidia 
Scale (SCHS) (104). 
Estimation of SNP heritability: 
Performed using GREML in GCTA 
(84). 
Estimation of genetic correlation 
between psychosis proneness 
scales: Performed using GREML in 
GCTA. Not performed for Schizoidia 
scale due to low SNP heritability 
estimate. 
GWAS: Univariate and multivariate 
GWASs. Summary statistics were 
further analysed using gene-based 
association testing. Not performed 
for Schizoidia scale due to low 
heritability estimate. 
SNP heritability estimation: HPS = 27.4%, 
PAS = 16.6%, PHAS = 26.6%, SAS = 20.4%, 
and SCHS = <0.1%. 
Estimation of genetic correlation between 
psychosis proneness scales: Identified a 
significant positive genetic correlation 
between PHAS and SAS scales (rG = 0.73), 
and a significant negative genetic 
correlation between HPS and PHAS scales 
(rG = -0.44), both of which are in the same 
direction as phenotypic and environmental 
correlations. All other pairwise genetic 
correlations between the scales were non-
significant. 
Univariate GWAS: Identified a genome-wide 
significant association for HPS in the TMC7 
gene, although there was no replication 
reported. Gene-based analysis of results 
identified 14 genes at significance after 
Bonferroni correction across the other four 
remaining psychosis proness scales. 
Bivariate GWAS: Combined analysis of HPS 
and PHAS identified a locus with borderline 
genome-wide significance nearest to 
AR1D1B.  
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Hatziman
olis et al., 
2018 (3)  
PRS; 
GxE 
Discovery sample: Athens Study 
of Psychosis Proneness and 
Incidence of Schizophrenia 
(ASPIS) (105): N = 875 
unrelated male conscripts 
(mean age = 20.8) at induction. 
N = 121 at 18-month follow up. 
Replication sample: Learning on 
Genetics of Schizophrenia 
Spectrum (LOGOS) replication 
sample (106): N = 690 
unrelated conscript males 
(mean age = 22.3). 
Discovery sample: Self-
report Schizotypal 
Personality 
Questionnaire (SPQ) 
(107) and Perceptual 
Aberration Scale (PAS) 
(102). Assessed at the 
time of conscription (see 
sample) and at follow up 
18-months later. 
Replication sample: Self-
report Schizotypal Traits 
Questionnaire (STQ) 
(108) assessed three 
dimensions of positive 
schizotypy. 
PRS analysis in discovery sample: 
Tested for association between 
schizophrenia (PGC2) (10) PRS and 
four SPQ dimensions (positive, 
negative, disorganisation, and 
paranoid), and PAS score at 
conscription. Years of education 
included as covariate. Tested for 
interaction effect between 
environmental stress 
(conscription) and schizophrenia 
genetic risk predicts SPQ factors 
and PAS score. Achieved by 
comparing schizophrenia PRS 
association results at conscription 
and follow up, and by comparing 
the difference in SPQ and PAS 
scores at the two time points, 
stratified by high and low 
schizophrenia PRS. 
PRS analysis in replication sample: 
Tested for association between 
STQ dimensions and schizophrenia 
genetic risk. An interaction effect 
between schizophrenia genetic risk 
and anxiety was assessed. 
PRS analysis in discovery sample: 
Significant negative genetic association 
identified between schizophrenia genetic 
risk and PAS scores, and positive, 
disorganisation and paranoid SPQ 
dimensions (no significant association 
found for negative SPQ dimension). In the 
replication sample, point estimates of 
association between schizophrenia PRS and 
STQ dimensions were also negative, 
although non-significant. One interaction 
identified, with lower PRS carriers showed 
higher PAS scores in the stressed condition 
compared to high PRS carriers (interactions 
not significant for SPQ dimensions).  PRS 
analysis in replication sample: An 
interaction between anxiety and 
schizophrenia risk significantly predicted 
lower paranoid ideation. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Liuhanen 
et al., 
2018 (47)  
PRS; 
GxE 
Discovery Sample: NFBC66 
(109): N = maximum of 4,223 
unrelated individuals assessed 
at age 31 years. 
Replication sample: The 
Schizophrenia Family sample: N 
= 144 (including relatives), 
31.2% with schizophrenia. 
Discovery sample: Self-
report Revised Social 
Anhedonia Scale 
(described above). 
Replication sample: Self-
report Revised Social 
Anhedonia Scale 
(described above).  
Genome-wide significant variation 
risk scoring: Genetic risk scores for 
schizophrenia were calculated 
based on 8 genome-wide 
significant SNPs identified in the 
PGC1 schizophrenia GWAS (80), 
and separately a 'broader genetic 
risk score' was calculated using the 
128 SNPs identified as genome-
wide significant in the PGC2 
schizophrenia GWAS (10). Only the 
PGC1 selected risk score was 
calculated in the replication sample 
due to limited genome coverage. 
Linear regression was used to 
assess the relationship between 
genetic risk, birth weight and social 
anhedonia. 
Individuals with low birth weight 
(<2.5 kg) were excluded. 
Genome-wide significant variation risk 
scoring: In NFBC66, no association between 
selected genetic risk score for 
schizophrenia and social anhedonia. 
Interaction analysis showed that high 
genetic risk of schizophrenia in 
combination with high birth weight 
predicted high social anhedonia. In the 
replication sample with schizophrenia this 
interaction effect was in the same direction 
but not significant.  
Taylor et 
al., 2017 
(46)  
PRS The Child and Adolescent Twin 
Study in Sweden (CATSS) (110). 
Relevant measures were 
completed at age 18 years. 
N = 5,368 individuals (including 
cotwins) assessed for parent-
report positive psychotic 
experiences. 
N = 5,518 individuals (including 
cotwins) assessed for self-
report positive psychotic 
experiences. 
Self- and parent-report 
positive psychotic 
experiences were 
assessed using the self- 
and parent-report 
versions of the 
Adolescent Psychotic-
Like Symptom Screener 
(APSS) questionnaire 
(111). 
PRS analysis: Tested for association 
between schizophrenia PRS (PGC2) 
(10) and positive experiences (self- 
and parent-report) using linear 
regression with a Generalised 
Estimating Equation (GEE) to 
account for the presence of twin-
pairs. 
PRS analysis: a significant association 
between schizophrenia genetic risk and 
self- (r2 = 0.15%) and parent-reported (r2 = 
0.17%) positive psychotic experiences. 
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Study Type Sample/s Relevant Measure/s Key Methods Key Results 
Pain et al., 
2018 (1)  
GWAS;
PRS; 
SNP h2 
Discovery sample: TEDS (82), 
ALSPAC (81) and CATSS (110) 
assessed for self-reported 
Paranoia and Hallucinations (N 
= 8,665), Anhedonia (N = 
6,579), Cognitive 
Disorganisation (N = 6,297), 
and parent-reported Negative 
Symptoms (N = 10,098). 
Individuals were assessed 
between 16-18 years. Sample 
sizes include cotwins. 
Replication sample: 
Independent subset of TEDS 
genotyped at a later stage than 
the TEDS sample above. N = 
2,359 individuals (including 
cotwins) assessed for self-
reported Anhedonia at age 16. 
Common measures of 
self-report Paranoia and 
Hallucinations, Cognitive 
Disorganisation, 
Anhedonia, and Parent-
report Negative 
Symptoms were derived 
across three samples to 
allow combined analysis 
of these four PENS 
domains. 
In TEDS items came from 
the SPEQ (see above). 
In ALSPAC and CATSS, 
items came from a 
selection of 
psychopathology 
questionnaires that 
mirrored items from 
SPEQ. 
Replication sample: 
Anhedonia assessed with 
SPEQ Anhedonia 
subscale. 
GWAS of 4 PENS domains using 
linear regression and GEE to 
account for the presence of twin-
pairs. 
Estimation of SNP heritability: SNP 
heritability of the four PENS 
domains estimated using GREML in 
GCTA (84) and LD-Score regression 
(53). 
PRS analysis: Tested for association 
between schizophrenia (PGC2) 
(10), bipolar disorder (86) and 
major depression (PGC1) (85) 
PRSs, and the four PENS domains 
using linear regression with a GEE 
to account for twin-pairs. Post-hoc 
analysis of the association between 
schizophrenia PRS and Paranoia 
and Hallucinations when excluding 
zero-scorers was also performed. 
Genetic covariance estimation: 
Genetic covariance between 
schizophrenia, bipolar disorder, 
major depression, and the four 
PENS domains was estimated using 
AVENGEME analysis (112) of PRS 
association results, and LD-Score 
Regression (113). 
GWAS: Genome-wide association analysis 
of four PENS domains returned 1 locus 
achieving genome-wide significance and 37 
loci at suggestive significance (p<1×10-5). 
The genome-wide significant association 
was for Anhedonia and was within the IDO2 
gene, a key enzyme in the kynurenine 
pathway. 
Estimation of SNP heritability from GREML: 
Paranoia and Hallucinations = 2.8%, 
Anhedonia = 8.8% Cognitive 
Disorganisation = 5.9%, and Negative 
Symptoms = 5.9% (Figure 1). LD-score 
estimates ranged from 6.6%-21.5% (Figure 
1). 
PRS analysis: Significant association 
between the schizophrenia PRS and 
Anhedonia (r2 = 0.08%), Cognitive 
disorganisation (r2 = 0.08%), and Negative 
Symptoms (r2 = 0.09%) but not (initially) 
for Paranoia and Hallucinations. Post-hoc 
analysis showed a significant association 
between schizophrenia PRS and Paranoia 
and Hallucinations when excluding 
individuals scoring zero on that domain (r2 
= 0.09%). PRS analysis also identified an 
association between major depression PRS 
and Anhedonia (r2 = 0.11%) and Parent-
report Negative Symptoms (r2 = 0.08%). A 
negative association between Paranoia and 
Hallucinations and genetic risk for bipolar 
disorder was identified (r2 = 0.12%). 
Genetic covariance estimation: AVENGEME 
analysis confirmed the significant 
associations identified by PRS analysis and 
identified other additional significant 
genetic covariance estimates. 
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Note. Type column shows which methods were included in study. AVENGEME, Additive variance explained and number of genetic 
effects methods of estimation; LD, linkage disequilibrium; PGC, Psychiatric Genomics Consortium; PRS, polygenic risk scores; SNP, single 
nucleotide polymorphism; PENS, psychotic experiences and negative symptom traits; IQ, intelligence quotient; GCTA, Genome-wide 
Complex Trait Analysis; GREML, genomic-relatedness-matrix restricted maximum likelihood; ADHD, attention deficit hyperactivity 
disorder; GWAS, genome-wide association study; SNP h2, SNP heritability; GxE, genome-wide gene-environment interaction analyses.
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allele frequency; ERP, event-related potential; EEG, electroencephalogram; 
GWAS, genome-wide association study; NFBC, Northern Finland Birth Cohort; 
PGC, Psychiatric Genomics Consortium; PRS, polygenic risk scoring; rGE, gene-
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